Compare USNA & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | AVXL |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.0M | 289.1M |
| IPO Year | 1996 | 2013 |
| Metric | USNA | AVXL |
|---|---|---|
| Price | $18.90 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 84.1K | ★ 852.5K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $1,060,902,000.00 | N/A |
| Revenue This Year | $3.90 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | $33.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.60 | $2.61 |
| 52 Week High | $38.32 | $13.99 |
| Indicator | USNA | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 43.60 |
| Support Level | $18.80 | $2.93 |
| Resistance Level | $21.21 | $3.76 |
| Average True Range (ATR) | 0.81 | 0.18 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 31.45 | 23.02 |
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.